ArticleFrontiers in oncology2026
Pancreas-preserving segmental duodenectomy for duodenal malignancy: two case reports.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extent of resection required for duodenal malignancy has long been debatable. Compared with pancreaticoduodenectomy (PD), pancreas-preserving segmental duodenectomy (PPSD) is a less demolitive procedure that provides definitive treatment for a range of duodenal pathologies, including adenocarcinoma. However, the rarity of these malignancies limits large-scale clinical studies on the feasibility and safety of PPSD. Thus, case reports and small case series may provide some clinical guidance for this rare situation. We herein report two cases of patients with duodenal malignancy who were treated with PPSD. Case 1 was a 36-year-old female patient, who was diagnosed with adenocarcinoma of the hepatic flexure with synchronous invasion of the descending portion of the duodenum. After 4 cycles of neoadjuvant chemotherapy, she received radical right colectomy and PPSD. Case 2 was a 45-year-old male patient, who was found to have a metachronous metastasis in the horizontal portion of the duodenum 14 months after laparoscopic extended right colectomy with complete mesocolic excision for transverse colon adenocarcinoma. The duodenal lesion was confirmed by imaging, endoscopic, and pathological examinations. He received PPSD combined with a partial resection of the uncinate process of the pancreas. Postoperative pathology confirmed R0 resection in both cases, and both patients had an uneventful recovery. These cases provide further evidence supporting the feasibility and safety of PPSD for non-ampullary duodenal tumors. However, the long-term oncological outcomes are still unclear; therefore, further studies with longer follow-up and larger sample sizes are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.